New study aims to uncover hidden clues in rare liver disease
NCT ID NCT07639996
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 45 adults with alpha-1 antitrypsin deficiency (a genetic condition that can cause liver damage) to learn how the disease progresses. Researchers will analyze stored blood and liver tissue samples to find biomarkers and understand the molecular pathways involved. The goal is to improve monitoring and eventually guide future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could identify blood markers to better predict and monitor liver disease in people with alpha-1 antitrypsin deficiency.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test any therapy, and results may take years to translate into clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- RNA editing drug WVE-006 enters first human safety trial
- Can a smartphone breathing game help Alpha-1 patients breathe easier?
- Gene-Editing shot aims to fix rare lung and liver disease
- Hidden gene behind breathlessness? study tests link to rare lung condition
- New drug YOLT-202 tested in early trial for rare lung and liver disease